<?xml version="1.0" encoding="UTF-8"?>
<p>Cholinergic dysfunction, amyloid-
 <italic>Î²</italic> neurotoxicity, oxidative damage and inflammation have been targeted for treatment of AD but with limited success [
 <xref rid="B23-brainsci-10-00964" ref-type="bibr">23</xref>,
 <xref rid="B24-brainsci-10-00964" ref-type="bibr">24</xref>]. Studies indicate that antioxidants (vitamins E and C) and non-steroidal anti-inflammatory drugs slow the progression of AD [
 <xref rid="B25-brainsci-10-00964" ref-type="bibr">25</xref>,
 <xref rid="B26-brainsci-10-00964" ref-type="bibr">26</xref>,
 <xref rid="B27-brainsci-10-00964" ref-type="bibr">27</xref>,
 <xref rid="B28-brainsci-10-00964" ref-type="bibr">28</xref>,
 <xref rid="B29-brainsci-10-00964" ref-type="bibr">29</xref>,
 <xref rid="B30-brainsci-10-00964" ref-type="bibr">30</xref>]. Hormone replacement therapy has also been tried as a therapeutic strategy. Though it performed better than tacrine [
 <xref rid="B31-brainsci-10-00964" ref-type="bibr">31</xref>], it is no longer recommended, as it may increase the risk of adverse cardiovascular events and breast cancer [
 <xref rid="B32-brainsci-10-00964" ref-type="bibr">32</xref>].
</p>
